"The United Kingdom’s National Institute for Health and Care Excellence (NICE) has chosen not to recommend abiraterone acetate (Zytiga) with prednisone/prednisolone plus androgen deprivation therapy (ADT) as a treatment for patients with newly diagnosed, high-risk hormone-sensitive metastatic prostate cancer."
'“There are concerns that the trials may overestimate the effectiveness of abiraterone,” the agency wrote in the final appraisal document.'
onclive.com/view/nice-passe...
-Patrick